This site uses cookies to store information on your computer. Learn more x

Our Businesses

DSM’s business groups are clustered in coherent product and market combinations, with the business group directors reporting directly to the Managing Board.  


The Nutrition cluster is made up of DSM Nutritional Products and DSM Food Specialties. DSM Nutritional Products is one of the world’s leading producers of essential nutrients such as vitamins, carotenoids, nutritional lipids and other ingredients to the feed, food, pharmaceutical and personal care industries. DSM Food Specialties’ food enzymes, cultures, yeast extracts, savory flavors, hydrocolloids and other specialty ingredients are found in the world’s favorite dairy, baking, beverage and savory brands.


The Materials cluster is made up of DSM Engineering Plastics, DSM Dyneema and DSM Resins & Functional Materials. DSM Engineering Plastics is a global player in specialty plastics. These materials are used in components for the electrical and electronics, automotive, flexible food packaging and consumer goods industries. DSM Dyneema is the inventor, manufacturer and marketer of Dyneema®, the world’s strongest fiber™. DSM Resins & Functional Materials is a global producer of innovative, sustainable resins solutions for paints and industrial and optical fiber coatings.

Innovation Center

Besides supporting innovation in our core businesses and venturing activities, the DSM Innovation Center also aims to develop its Emerging Business Areas (EBAs). They comprise DSM Biomedical, focused on innovative materials for medical devices; DSM Bio-based Products & Services, which focuses on clean energy from crop residues as well as bio-chemicals with enzymes and yeasts for biomass conversion; and DSM Advanced Solar, which offers yield-boosting solutions for solar energy.


DSM created partnerships for our pharma activities (DSM Sinochem Pharmaceuticals in 2011 and Patheon in 2014) and for our bulk chemicals and composite resins businesses (ChemicaInvest in 2015) with the intention of ultimately exiting these businesses and maximizing their value:

  • In August 2017 Thermo Fisher Scientific Inc. completed the acquisition of Patheon. The total proceeds from the divestment of Patheon including an earlier IPO amounted to approximately €2 billion.
  • On 17 May 2018 ChemicaInvest announced the proposed sale of Fibrant (caprolactam) to Highsun Holdings Group Ltd. DSM estimates it will receive about €200 million in cash following the closing of the transaction.
  • On 29 June 2018 Bain Capital announced their proposed acquisition of DSM Sinochem Pharmaceuticals. DSM expects to receive approximately €275 million in cash following closing, including repayment of debt and after transaction costs.